State Street
OBIO icon

State Street’s Orchestra BioMed OBIO Stock Holding History

State Street’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Buy
516,050
+346,640
+205% +$1.42M ﹤0.01% 3304
2026
Q1 		$720K Buy
169,410
+10,377
+7% +$44.2K ﹤0.01% 3565
2025
Q4 		$660K Buy
159,033
+58,300
+58% +$235K ﹤0.01% 3613
2025
Q3 		$250K Sell
100,733
-29,400
-23% -$81.1K ﹤0.01% 3844
2025
Q2 		$349K Sell
130,133
-343,586
-73% -$1M ﹤0.01% 3694
2025
Q1 		$2.03M Buy
473,719
+26,007
+6% +$129K ﹤0.01% 3244
2024
Q4 		$1.79M Buy
447,712
+18,099
+4% +$97.2K ﹤0.01% 3351
2024
Q3 		$2.21M Buy
429,613
+47,308
+12% +$309K ﹤0.01% 3297
2024
Q2 		$3.12M Buy
382,305
+127,358
+50% +$738K ﹤0.01% 3131
2024
Q1 		$1.34M Sell
254,947
-30,963
-11% -$210K ﹤0.01% 3397
2023
Q4 		$2.61M Buy
285,910
+106,029
+59% +$724K ﹤0.01% 3227
2023
Q3 		$1.57M Buy
179,881
+38,044
+27% +$256K ﹤0.01% 3418
2023
Q2 		$993K Buy
141,837
+107,651
+315% +$1.63M ﹤0.01% 3581
2023
Q1 		$669K Buy
+34,186
New +$396K ﹤0.01% 3651

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

State Street's OBIO Position: Q2 2026 in Review

State Street increased its Orchestra BioMed (OBIO) stake by 205% in Q2 2026, buying an estimated $1.42M and bringing the position to 516,050 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #3304.

State Street first reported a position in OBIO in Q1 2023 and has held it in 14 quarters since. The position peaked at $3.12M in Q2 2024. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • State Street held 516,050 shares of Orchestra BioMed worth $2.23M as of Q2 2026.
  • State Street bought 346,640 Orchestra BioMed shares in Q2 2026, an estimated $1.42M.
  • Orchestra BioMed made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3304 holding.
  • State Street first reported a position in Orchestra BioMed in Q1 2023 and has held it in 14 quarters since.
  • State Street's Orchestra BioMed position peaked at $3.12M in Q2 2024.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.